RxDoctor Payments Data

David Moaddel, MD

Adult Medicine · West Hills, CANPI 1376808626

Payments from drug & device makers

$471in general payments, 2019–2025

Across 10 payments — averaging $47.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$196
  • Novartis$97
  • Pfizer$60
  • New Horizon Medical Solutions$53
  • Organogenesis Inc.$33
  • AbbVie$32

What the payments were for

  • Food & beverage$471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$196
Novartis3$97
Pfizer2$60
New Horizon Medical Solutions1$53
Organogenesis Inc.1$33
AbbVie1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$471 in reported general payments places this provider in the 60th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$2,769,846
Medicare patients
722
Services billed
5,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$31,068
Vancomycin Hcl21$4,481
Levothyroxine Sodium42$947
CeftriaxoneCeftriaxone Sodium13$946
CholestyramineCholestyramine (With Sugar)13$938
SynthroidLevothyroxine Sodium17$785
Potassium Chloride35$681
Atorvastatin Calcium91$624
Pantoprazole Sodium35$386
Amlodipine Besylate32$321
Losartan Potassium25$294
Temazepam32$262
Escitalopram Oxalate12$222
Omeprazole20$214
Simvastatin14$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$31,06840 claims
AbbVieSynthroid$32$78517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 221 adult medicine providers in California.

Other adult medicine in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →